PF-614 is under clinical development by Ensysce Biosciences and currently in Phase II for Post-Operative Pain. According to GlobalData, Phase II drugs for Post-Operative Pain have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PF-614’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PF-614 overview

PF-614 (oxycodone prodrug ER) is under development for the treatment of post surgical pain and substance (drug) abuse. The drug candidate is an extended-release formulation administered orally. It is an abuse-resistant opioid prodrug based on Bio-MD technology. PF-614 acts by targeting mu opioid receptor (MOR or OP3 receptor). It is developed based on Trypsin-Activated Abuse Protection (TAAP) technology. It is administered through nasal or inhalation route for the treatment of substance (drug) abuse.

Ensysce Biosciences overview

Ensysce Biosciences is a biotechnology company. It offers proprietary abuse-resistant opioid prodrug technology. The company’s pipeline products include PF614- TAAP oxycodone for pain and respiratory diseases, PF8001 / PF8026- TAAP amphetamine to deter prescription drug abuse at the molecular level, OUD is to abuse-deterrent technology for Opioid Use Disorder. The company offers services such as clinical programs, preclinical programs, TAAP technology, pain medications, drug delivery, MPAR technology, proprietary prodrug technology, abuse resistant technology among others. It provides its products and services to the healthcare, medical and pharmaceutical sectors. Ensysce Biosciences is headquartered in San Diego, California, the US.

For a complete picture of PF-614’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.